Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP Chemotherapy + Trastuzumab +/- Pertuzumab in HER2-Positive Breast Cancer
NCT07115095Completed
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of pertuzumab in breast cancer (2 arms). Primary endpoints: Overall Response Rate at 18 weeks and Disease Control Rate at 18 weeks. Started Jan 2021; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07115095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115095.